Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

Dow Jones

Apr 10

1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 10, 2026 07:45 ET (11:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2626192182"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2626192182\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2626192182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626192182","market":"sg","top_or_hot":-1,"title":"Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-10 19:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211331839.USD","symbol_name":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626192182","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626192182","pubTimestamp":1775821500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","NVS":"诺华","BK4578":"CAR-T","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4588":"碎股","ISBC":"投资者银行","BK4007":"制药","BK4211":"区域性银行","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"诺华投资者在业绩疲软的情况下将重点关注产品线更新——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"ISBC":1.5},"content_text":"1144 GMT - Novartis investors are likely to focus on upcoming updates from the Swiss drugmaker's late-stage drug pipeline, given that the company has already flagged that its results will be weak in the first half, UBS analysts say. Investors will be keen for updates on drug candidates such as remibrutinib for multiple sclerosis, pelacarsen for cardiovascular risk and del-desiran for muscle disease myotonic dystrophy type 1, according to UBS. The company has been dealing with generic competition for heart drug Entresto, leukemia treatment Tasigna, and blood-platelet booster Promacta for a while and the rate of sales erosion is likely to accelerate in the first quarter, UBS says in a research note. Nevertheless, other drugs such as Kisqali for breast cancer and Scemblix for leukemia should deliver solid results, the analysts say. Shares rise 0.6%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:45 ET (11:45 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}